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Abstract 
Objective: We wished to relate severity of Parkinson’s disease (PD) with 
cognitive function in relation to cerebral blood flow (CBF). 
Methods: Eighty-one consecutive PD patients were enrolled in this study. We 
used Mini-Mental State Examination (MMSE) and Wechsler Adult Intelligence 
Scale-Third edition (WAIS-III) to evaluate cognitive functions, and 
three-dimensional stereotactic ROI template (3DSRT) and Statistical Parametric 
Mapping (SPM) 8 to evaluate single photon emission CT (SPECT) recordings of 
regional CBF. 
Results: The mean MMSE score of PD patients was 27.4 ± 2.4. The scores of 
most patients were higher than 23/30. On the other hand, the mean Full-scale IQ 
of PD patients was 88.4 ± 17.3 in WAIS-III, which was lower than that of normal 
controls. In particular, visuospatial function score of most patients was lower. 
There were significant correlation between cognitive scores and Hoehn & Yahr 
stage and hallucinatory episodes. PD Patients with stage III and IV showed 
significant deterioration in cognitive functions compared to stage II patients. 
Analysis of CBF revealed relative reductions in perfusion in the cerebral cortex 
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relative to that in normal control. SPM 8 showed that cognitive functions in PD 
patients were positively correlated with rCBF in the thalamus and cingulate 
gyrus. 
Conclusions: This is the study to demonstrate the cognitive impairments in PD 
patients using WAIS-III. Visuospatial dysfunction might be caused by decrease 
in rCBF in the parietal and occipital lobes and dorsolateral prefrontal cortex. The 
severity of cognitive impairments in PD patients was correlated with disease 
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1. Introduction 
Cognitive impairments are one of the most common non-motor symptoms in 
patients with Parkinson’s disease (PD). Subtle cognitive impairments that 
usually progress to more severe cognitive impairments and dementia may exist 
from the initial stage of PD. Cognitive impairments may be ascribed to 
dopaminergic depletion and failure of the fronto-striatal basal ganglia circuits [1]. 
Patients with PD have a four- to six-fold increase in the risk of developing 
dementia compared to the age-matched general population [2]. In a follow-up 
study, the prevalence of PD with dementia (PDD) was 20% at 5 years after the 
onset, and increased to 45% at 15 years and 83% at 20 years [3]. Since the 
mortality is higher in patients with PDD than in non-demented patients [4], the 
evaluation of cognitive functions in patients with PD is very important. 
 In the present study, we evaluated the cognitive functions in patients with PD 
and examined the correlation between cognitive functions and patient-related 
factors, motor symptoms, and mood states. Additionally, the regional cerebral 
blood flow (rCBF) in patients with PD was assessed in terms of the results of 
cognitive functions. We hypothesized that rCBF in patients with PD may be 
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lower than that of normal controls and that the results of cognitive functions and 




The subjects were 81 patients with PD that visited our institute between July 
2008 and November 2011. Disease severity of patients with PD in this study was 
determined by Hoehn & Yahr (H&Y) stage. Hallucinations, ADL, and motor 
symptoms were evaluated by the Unified Parkinson’s Disease Rating Scale 
(UPDRS). Mood states were evaluated by a profile of mood states (POMS) [5]. 
The mean age of patients was 62.8 ± 7.4 years. Mean disease duration was 11.9 
± 5.4 years. Levodopa equivalent daily dosage (LEDD) was 966.5 ± 390.7 mg. 
The mean H&Y stage score in the drug-on condition was 2.8 ± 0.7. When we 
classified patients with PD according to H&Y stage, there were 32 stage II 
patients, 38 stage III patients, and 11 stage IV patients. In the evaluation of 
UPDRS, the hallucinations score was 0.4 ± 0.5; the ADL score was 7.8 ± 6.3; the 
motor score was 13.1 ± 10.4; the tremor score was 0.5 ± 1.1; the rigidity score 
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was 2.5 ± 2.8; the akinesia score was 3.8 ± 4.3; and the postural instability score 
was 3.0 ± 2.5. In the evaluation of POMS, the Tension-Anxiety score was 51.5 ± 
9.1; the Depression score was 50.1 ± 9.4; the Anger-Hostility score was 44.3 ± 
7.7; the Vigor score was 40.1 ± 8.2; the Fatigue score was 47.9 ± 8.4; and the 
Confusion score was 56.7 ± 10.6. 
Written informed consent was obtained from every patient before the study. 
The ethical committee of Okayama University Hospital has approved the use of 
human subjects for this study. 
 
2.2. Evaluation of cognitive functions 
All patients with PD were assessed using the Mini-Mental State Examination 
(MMSE) and the Wechsler Adult Intelligence Scale-Third edition (WAIS-III). 
Trained clinical psychologists and speech therapists conducted the 
neuropsychological tests for all patients. Neuropsychological tests were 
performed for patients with drug-on condition. When we evaluated the cognitive 
functions of patients with PD with motor fluctuation, we performed 
neuropsychological tests for patients with the drug-on condition as judged by the 
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patient’s self-report. We stopped the tests when patients with PD presented with 
motor fluctuations. 
Twelve subtests in WAIS-III were conducted for patients with PD in this study. 
We excluded Object assembly and Symbol search in order to reduce patient 
fatigue. In accordance with the protocol for WAIS-III, raw scores were converted 
to age-corrected scaled scores in the normal control group, which consists of 
1381 healthy adult Japanese selected randomly [6]. The mean IQ of normal 
control in WAIS-III is set from 90 to 109 [6]. WAIS-III scores are shown as 
comparison of IQ with scores of normal control [6]. Next, we calculated the 
summary scores of Full-scale IQ (FIQ), Verbal IQ (VIQ), and Performance IQ 
(PIQ), and group indexes for Verbal Comprehension (VC), Working Memory 
(WM), and Perceptual Organization (PO). 
 
2.3. rCBF study 
Single-photon emission computed tomography (SPECT) was performed as 
reported previously [7]. All patients with PD received 99mTc ethyl cysteinate 
dimer SPECT (Fujifilm RI Pharmaceuticals Ltd., Tokyo, Japan). SPECT was 
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performed for patients with the drug-on condition. We used the Patlak plot 
method to quantify the rCBF in patients with PD [8]. After all patients underwent 
SPECT, we evaluated rCBF by using the three-dimensional stereotactic ROI 
template (3DSRT) and Statistical Parametric Mapping (SPM) 8 (Department of 
Cognitive Neurology, UCL, London, UK). 
3DSRT is a fully automated rCBF quantification program with 636 regions of 
interest (ROIs) in total [9]. We quantified the blood flow in each ROI as the value 
in millilitres per 100 g/min and showed it in 12 segments: callosomarginal, 
precentral, central, parietal, angular, temporal, occipital, pericallosal regions, 
lenticular nucleus, thalamus, hippocampus, and cerebellum. The 3DSRT values 
of patients with PD are compared to the normal control in these segments (rCBF 
of PD patient’s / rCBF of normal control × 100 [%]). We used the scores of 
normal control of healthy adult Japanese in 3DSRT research shown in a 
previous study by Matsuda [10]. 
The correlation between cognitive functions and rCBF was analyzed using 
SPM 8 [11]. All SPM calculations were performed using Matlab version 2012a 
(MathWorks, Sherborn, Massachusetts, USA). The SPECT images were 
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spatially normalized to the standardized brain template [12]. The normalized 
images were smoothed to account for variations in subtle anatomic structures 
[13]. Statistical correlation between cognitive functions and rCBF was explored 
voxel by voxel by setting each patient’s IQ as a covariate of interest. Significance 
was accepted if the clusters survived a corrected threshold of p < 0.05. We 
showed anatomical regions with correlation between cognitive functions and 
rCBF using Talairach Daemon software [14]. 
 
2.4. Statistical analysis 
First, all data are shown as mean ± standard deviation (SD) in MMSE and 
WAIS-III. Second, we used a two-tailed Pearson’s correlation coefficient test 
between cognitive functions (MMSE, WAIS-III) and patient-related factors (age, 
disease duration, LEDD, hallucinations), motor symptoms (H&Y stage and 
UPDRS), and mood states (POMS). We conducted Bonferroni corrections for 
multi-factor analyses in UPDRS items. Finally, we focused on the H&Y stage 
that was most strongly correlated with cognitive functions. We conducted a 
one-way analysis of variance (ANOVA) to assess the significance of mean 
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differences in demographic data and the results of cognitive functions in three 
groups (II, III, and IV) classified by H&Y stage and then performed a post hoc 
Bonferroni test. All statistical analyses were performed with SPSS 15.0 for 
Windows. Statistical significance was set at p < 0.05. 
 
3. Results 
3.1. Cognitive functions in patients with PD 
The mean MMSE score of patients with PD was 27.4 ± 2.4 (range: 21–30). Five 
patients (6.1%) were under the cut-off point, that is, 23/30. The scores of most 
patients were more than 23/30 in MMSE. 
The mean FIQ of patients with PD was 88.4 ± 17.3 (range: 57–125) in WAIS-III 
(Supplementary Table 1). The mean FIQ was lower than that of normal controls. 
The VIQ and PIQ were 92.9 ± 16.4 (range: 65–129) and 85.2 ± 17.4 (range: 
53–120), respectively. The VIQ was within the normal range; however, the PIQ 
was lower than that of normal controls. In the group index, the VC index was 
93.7 ± 15.9 (range: 65–129). The WM index was 93.1 ± 13.3 (range: 60–130). 
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The VC and WM indexes were within the normal range. The PO index was 88.2 
± 17.7 (range: 52–125). The PO index was lower than that of normal controls. All 
verbal subtest scores of patients with PD were within the normal range. The 
Block design, Picture arrangement, and Digit symbol cording scores were lower 
than those of normal controls. 
 
3.2. Correlation between cognitive functions and factors in patients with PD 
MMSE score was correlated with age, H&Y stage, and hallucinations (Table 1). 
FIQ was correlated with H&Y stage and hallucinations. VIQ was correlated with 
H&Y stage, hallucinations, and Anger-Hostility. PIQ was correlated with H&Y 
stage and hallucinations. VC index was correlated with H&Y stage and 
Anger-Hostility. WM index was correlated with H&Y stage and Confusion. PO 
index was correlated with H&Y stage and hallucinations. 
 
3.3. Cognitive impairments and H&Y stage in patients with PD 
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The demographics were not significantly different in groups of each H&Y stage 
(mean age: stage II: 62.6 ± 8.7, III: 63.0 ± 5.3, IV: 63.8 ± 9.4; years of education: 
II: 12.7 ± 2.0, III: 12.6 ± 1.5, IV: 12.5 ± 1.7). We evaluated the cognitive functions 
in each H&Y stage group (II, III, and IV). The mean MMSE score was not 
significantly different among the three groups (stage II: 27.9 ± 1.9, III: 27.2 ± 2.7, 
IV: 26.4 ± 2.4). WAIS-III scores in each H&Y stage group are shown in Fig. 1A. 
The mean FIQ of stage II patients was higher than that of stage III and IV 
patients. Similarly, the mean VIQ and PIQ of stage II patients were higher than 
that of stage III and IV patients. In the group index, the mean VC index of stage II 
patients was significantly higher than that of stage III patients (Fig. 1B). The 
mean WM and PO indexes of stage II patients were significantly higher than that 
of stage III and IV patients. 
 In verbal subtests, the Similarities score of stage II patients was higher than 
that of stage III and IV patients (Fig. 1C). The Vocabulary and Arithmetic scores 
of stage II patients were also higher than that of stage III patients. The Letter 
number sequencing score of stage II patients was higher than that of stage IV 
patients. There was no significant difference in the other subtests, including 
Information, Comprehension, and Digit span. All of the performance subtest 
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scores of stage II patients were higher than that of stage III and IV patients in 
Picture completion, Block design, Matrix reasoning, Picture arrangement, and 
Digit symbol cording (Fig. 1D). 
 
3.4. rCBF study 
3DSRT demonstrated that the rCBF of patients with PD was lower in the bilateral 
callosomarginal, precentral, central, parietal, angular, temporal, occipital regions, 
and cerebellum compared to the normal controls (Table 2). On the other hand, 
the rCBF of patients with PD was comparatively normal in the pericallosal 
segment, lenticular nucleus, thalamus, and hippocampus. 
SPM 8 showed correlation between FIQ and rCBF in patients with PD (Fig. 2). 
The strong correlation between FIQ and rCBF, that is, the increased rCBF in 
patients with high FIQ and the decreased rCBF in patients with low FIQ, is 
shown in red and yellow. FIQ was positively correlated with rCBF in the thalamus, 
hypothalamus, and cingulate gyrus. VIQ was positively correlated with rCBF in 
the frontal lobe, including the frontal and inferior frontal gyrus, left temporal pole, 
left hippocampus, and pons. PIQ was positively correlated with rCBF in the 
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frontal lobe (such as the superior frontal gyrus and dorsolateral prefrontal area), 
the parietal lobe (such as the lingual gyrus), and the occipital lobe. 
 
4. Discussion 
We found that the MMSE score of patients with PD was usually high and few 
patients had a score below 23/30. Another study showed that the mean MMSE 
score of patients with PD was 27.4 and 17% of patients had a score below 23/30 
[15]. The mean MMSE score was almost the same between ours and the study. 
Cognitive impairments in patients with PD are characterized by memory, 
visuospatial, and executive dysfunction. However, MMSE may be inadequate to 
evaluate these cognitive dysfunctions in patients with PD. 
In our study, patients with PD had impaired cognitive functions in the evaluation 
of WAIS-III. Schadt used part of WAIS-III to evaluate cognitive functions in 
patients with PD [16], but study that was used WAIS-III is few. In our study, the 
PO index of patients with PD was low scoring, which indicated that most patients 
with PD had visuospatial dysfunction. Another study showed that visuospatial 
dysfunction in patients with PD appeared in visuospatial tasks on executive 
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function such as planning and attention [17]. Visuospatial function in patients 
with PD may be impaired due to executive dysfunction. Therefore, in our study, 
patients with PD received significantly low scores in block design of WAIS-III that 
is visuospatial function tests involving executive function. 
The present study found that cognitive functions were significantly correlated 
with H&Y stage in patients with PD. In other studies, cognitive functions in 
patients with PD were correlated with age, H&Y stage [3], and neuropathological 
stage [18]. Patients with stage II PD retained cognitive functions to some extent 
in our study compared to normal controls. However, patients with stage III and IV 
PD had significantly impaired cognitive functions, including language function, 
working memory, and visuospatial function than that of stage II patients. 
Cognitive functions were also significantly correlated with hallucinations in our 
study. Hallucinations may occur in the course of degenerative dementias 
besides PDD, such as dementia with Lewy bodies and Alzheimer’s disease [19]. 
The prevalence of hallucinations is approximately 40% in patients with PD and 
the emergence of visual hallucinations is high [19]. The performance of PD 
patients with hallucinations was significantly worse in terms of cognitive 
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functions when compared to patients without hallucinations [20]. Therefore, 
hallucinations in patients with PD may be a predictor of cognitive impairments, 
although further investigations with dedicated assessment tools for 
hallucinations are needed. 
3DSRT revealed that patients with PD had hypoperfusion in the 
callosomarginal segment and the cerebral cortex, including the frontal, temporal, 
parietal, and occipital lobes. In the previous research in meta-analysis of 
quantitative results, global CBF of cerebral cortex was decreased in patients 
with PD [21]. SPM 8 showed that cognitive functions in patients with PD, in the 
WAIS-III evaluation, were correlated with rCBF in the thalamus and cingulate 
gyrus. The thalamus is the main area in the fronto-striatal basal ganglia circuits. 
These circuits may be critical for cognitive functions and behavior control [22]. 
Dysfunction of these circuits may cause cognitive impairments, especially in 
language and executive dysfunctions [23]. Therefore, the cognitive function 
decline in patients with PD may be caused by a decrease in rCBF in the 
thalamus and cingulate gyrus. 
Verbal function in patients with PD was correlated with rCBF in the left temporal 
and left hippocampus in our study. The role of the left hippocampus is 
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associated with verbal memory [24]. The MMSE score was significantly 
correlated only with left hippocampal perfusion [25]. We found normal rCBF in 
the left hippocampus in patients with PD. Therefore, in our study, verbal function 
in patients with PD may be preserved in WAIS-III, and patients with PD may 
score high in MMSE, in which the verbal function fairly affects the scores. 
Visuospatial function was correlated with rCBF in the parietal and occipital 
lobes and the dorsolateral prefrontal area. The lingual gyrus and occipital lobe 
play an important role in patients attempting spatial recognition. The dorsolateral 
prefrontal cortex plays a critical role in executive function after spatial recognition. 
A decrease in rCBF in these areas reflects dysfunction in cortical visual 
processing [26]. Therefore, hypoperfusion of the parietal and occipital lobes and 
the dorsolateral prefrontal cortex in patients with PD may cause visuospatial 
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Figure Captions 
Fig. 1. WAIS-III scores in each Hoehn & Yahr stage group 
The mean scores in each Hoehn & Yahr stage group are shown in IQ (A), Group 
index (B), Verbal subtest (C), and Performance subtest (D). The black bar 
represents scores in stage II patients. The white bar represents scores in stage 
III patients. The gray bar represents scores in stage IV patients. The error bar 
shows standard deviation. The high score indicates good performance. A 
significant difference was found between stage II and III and stage II and IV 
patients (** p < 0.01, * p < 0.05). 
 
Fig. 2. Correlation between cognitive functions and rCBF in patients with 
PD 
The strong correlation between cognitive functions and rCBF in patients with PD 
is shown in red and yellow (p < 0.05). 
